For the past few years, some of us have been quietly concerned about the true value of MRI scans and the accuracy of PI-RADS scores in evaluation of a patient’s risk for the presence of clinically significant prostate cancer. This is a complex issue … but data from a large, recently completed study has now validated these concerns. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: MRI, PI-RADS, risk, scan, score | 25 Comments »
For several years, Dr. Jelle Barentz in the Netherlands has been a prominent advocate for the idea that we might be able to use imaging methodologies (prostate “manograms”, like breast mammograms for women) to screen for risk of prostate cancer — either along with or instead of PSA testing. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biparametric, Diagnosis, fast, MRI, multiparametric, risk, scan | 2 Comments »
In his latest epistle to the medical community on the MedPage Today web site, prostate cancer patient Howard Wolinsky writes about the need (or lack of need) for the use of gadolinium-containing contrast agents associated with the conduct of multiparametric MRI (mpMRI) scans. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: contrast, gadolinium, MRI, scan | 4 Comments »
The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active, atenolol, biopsy, genomic, MRI, PI-RADS, predict, prognosis, scan, surveillance, test | 4 Comments »
Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, biopsy, Diagnosis, fusion, MRI, MRi-guided, MRI/TRUS, prognosis, scan | 3 Comments »
Under the heading “Rats, my PSA went up. Do I need another bleeping biopsy?” Howard Wolinsky provides us with the latest “lowdown” on his 8-year-long prostate cancer journey on active surveillance. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active, biopsy, MRI, repeat, surveillance | Leave a comment »
Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, clinically significant, data, Gleason 7, MRI, outcome, PI-RADS, prediction, PSA, risk | 5 Comments »
A report in the journal Urology (the so-called “Gold Journal”) from a team of researchers at Yale School of Medicine has shown that having a prostate MRI as part of the work-up for a patient initially diagnosed with low-risk prostate cancer roughly doubled the chance that such a patient was initially managed on “observation”. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, monitoring, MRI, observation, risk, scan | 2 Comments »
We have recently started to see a flurry of publications of papers suggesting that biparametric MRI (bpMRI) scans may be “better” — or at least more cost-effective — than multiparametric MRI (mpMRI) scans in the diagnosis of localized forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: biparametric, bpMRI, mpMRI, MRI, multiparametric, scan | Leave a comment »
Many prostate cancer patients — and particularly those who don’t like the idea of prostate biopsies — think that if one uses MRI-guided biopsies alone one might only need to have one or two biopsy cores taken to accurately diagnose prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, cores, fusion, MRI, MRI/TRUS, number, scan | 7 Comments »
A new article in this week’s New England Journal of Medicine has just reported the full results of the so-called PRECISION trial of MRI-targeted vs. standard biopsy techniques in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, MRI, outcome, standard, targeted | 5 Comments »
Slowly but perhaps inexorably we seem to be seeing increasing scientific and clinical justification for the argument that all men thought to be at risk for a diagnosis of prostate cancer should be given an MRI scan prior to any form of prostate biopsy. … READ MORE …
Filed under: Diagnosis | Tagged: biopsy, cost, efficiency, MRI, standard | 8 Comments »
A recent report in Urology Practice makes what we see as a somewhat odd statement about what patients may be willing to pay for an MRI/TRUS fusion-guided biopsy as opposed to a TRUS-guided prostate biopsy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: biopsy, cost, fusion, MRI | 4 Comments »
Staff at the Urologic Oncology Branch of the National Cancer Institute have just published the results of a survey evaluating current knowledge of (some) specialist urologists and urologic oncologists about the roles of MRI scanning in the diagnosis of prostate cancer and how they are integrating the use of MRI scanning and MR-guided biopsies into their clinical practice. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: acceptance, biopsy, MR-targeted, MRI, uptake | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 